EGFR and non-small cell lung carcinoma: Gefitinib (GEF), a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has become a widely used small-molecule targeted drug in the treatment of non-small cell lung cancer (NSCLC).